| CEO Name | Waleed Nasser. |
| Nationality | Palestine |
| Net Worth Estimation | $2 million |
Waleed Nasser, current CEO of Jerusalem Pharmaceuticals, is estimated to have a net worth of around $2 million primarily due to his executive compensation, company equity holdings, and related business assets within the regional pharmaceutical sector. Public disclosure on his exact financial portfolio is limited, so this figure reflects industry benchmarks for executives in similar positions and markets.
Waleed Nasser's estimated net worth of $2,000,000 is just 2.2% of the maximum and 20% of the minimum CEO net worth in the healthcare category, which ranges from $10,000,000 to $90,000,000. This places him significantly below both the average and typical net worth for CEOs in this industry.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Waleed Nasser. Performance in Jerusalem Pharmaceuticals
Waleed Nasser, CEO of Jerusalem Pharmaceuticals, demonstrates visionary leadership by driving strategic growth and innovation in the pharmaceutical sector. His decisive, data-driven decision-making fosters operational efficiency and robust market expansion. Under his guidance, the company has significantly enhanced product development and global presence, boosting overall performance and shareholder value.
Latest News
Jerusalem Pharmaceuticals and CEO Mohammed Mahmoud Masrouji: Overview and Recent Performance
Jerusalem Pharmaceuticals, founded in 1969 and led by CEO Mohammed Mahmoud Masrouji, develops and markets around 300 pharmaceutical products across Palestine and internationally, generating approximately $44.2 million in revenue with a net profit margin of 17.49% as of mid-2025. The company continues operations in multiple dosage forms including tablets and injectables, serving markets in the Middle East and North Africa, with a market capitalization near $72 million.
Source: http://simplywall.st/stocks/ps/pharmaceuticals-biotech/plse-jph/jerusalem-pharmaceuticals-shares